

Food and Drug Administration
Center for Biologics Evaluation and Research
BIOLOGICAL RESPONSE MODIFIERS ADVISORY COMMITTEE
MEETING #34
February 28, 2002
Holiday Inn, Silver Spring, MD

8:00 a.m.	Welcome and Introduction Daniel Salomon, M.D., Chair
8:10	Meeting Statement Gail Dapolito, Executive Secretary
Topic I:	Update Retroviral Gene Therapies for the Treatment of Patients with Severe Combined Immunodeficiency – Safety Issues
8:15	FDA Introduction Philip D. Noguchi, M.D., Office of Cellular, Tissues, and Gene Therapies Carolyn Wilson, Ph.D., Office of Cellular, Tissues, and Gene Therapies
	Guest Presentations
8:45	Marina Cavazzana-Calvo, M.D., Ph.D. Necker University Hospital
9:30	Q&A
9:45	Break
10:00	Claudio Bordignon, M.D. Istituto Scientifico HS Raffaele
10:25	Dr. Adrian Thrasher, M.D., Ph.D. University College London
10:50	Q&A
11:05	Open Public Hearing
12:05 p.m.	Lunch
1:00 p.m.	FDA Presentation of Questions
1:05	Committee Discussion of Questions
3:00 p.m.	Adjourn